首页> 外文OA文献 >Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi
【2h】

Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi

机译:医学遗传学中的药物修复:鉴定化合物作为潜在的抗真菌药物,以克服多药抗性真菌的出现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immunodepression, whether due to HIV infection or organ transplantation, has increased human vulnerability to fungal infections. These conditions have created an optimal environment for the emergence of opportunistic infections, which is concomitant to the increase in antifungal resistance. The use of conventional antifungal drugs as azoles and polyenes can lead to clinical failure, particularly in immunocompromised individuals. Difficulties related to treating fungal infections combined with the time required to develop new drugs, require urgent consideration of other therapeutic alternatives. Drug repurposing is one of the most promising and rapid solutions that the scientific and medical community can turn to, with low costs and safety advantages. To treat life-threatening resistant fungal infections, drug repurposing has led to the consideration of well-known and potential molecules as a last-line therapy. The aim of this review is to provide a summary of current antifungal compounds and their main resistance mechanisms, following by an overview of the antifungal activity of non-traditional antimicrobial drugs. We provide their eventual mechanisms of action and the synergistic combinations that improve the activity of current antifungal treatments. Finally, we discuss drug repurposing for the main emerging multidrug resistant (MDR) fungus, including the Candida auris, Aspergillus or Cryptococcus species.
机译:免疫吸引力,无论是由于艾滋病毒感染还是器官移植,都会增加对真菌感染的人类脆弱性。这些条件为机会性感染的出现产生了最佳环境,这伴随着抗真态抗性的增加。用常规的抗真菌药物作为氮孔和聚烯部分可以导致临床失败,特别是在免疫润滑性的个体中。与治疗真菌感染有关的困难与开发新药物所需的时间相结合,需要紧急考虑其他治疗方法。药物修复是科学和医学界可以转向的最有前途和快速解决方案之一,成本低,安全优势。为了治疗危及生命的抗性真菌感染,药物重估导致了考虑众所周知的和潜在分子作为最后疗法。本综述的目的是提供目前抗真菌化合物及其主抗性机制的概述,概述了非传统抗菌药物的抗真菌活性的概述。我们提供了他们最终的行动机制和改善当前抗真菌治疗活性的协同组合。最后,我们讨论针对主要新兴多药物抗性(MDR)真菌的药物修复,包括Candida Auris,曲霉或隐睾物种。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号